Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 20:6:e42360.
doi: 10.2196/42360.

A Digital Self-help Intervention for Atopic Dermatitis: Analysis of Secondary Outcomes From a Feasibility Study

Affiliations

A Digital Self-help Intervention for Atopic Dermatitis: Analysis of Secondary Outcomes From a Feasibility Study

Dorian Kern et al. JMIR Dermatol. .

Abstract

Background: Atopic dermatitis (AD) is a common inflammatory skin disease characterized by dry skin, eczematous lesions, and an often severe pruritus. The disease may have a negative effect on quality of life and is also associated with symptoms of anxiety and depression. Few individuals with AD receive any form of behavioral intervention. Behavioral interventions for AD are potentially efficacious but need to be constructed so that they are safe, credible, and user-friendly. We have previously reported on a feasibility study that demonstrated that a self-management version of a digital intervention based on cognitive behavioral therapy (CBT) for AD can potentially be effective in reducing AD symptoms. The aim of this secondary report was to further examine treatment feasibility and preliminary effects on dermatological quality of life, itching sensations, depressive symptoms, and perceived stress.

Objective: This is a secondary report on intervention credibility, usability, adverse events, and preliminary effects on secondary measures of a self-management digital intervention for atopic dermatitis.

Methods: In total, 21 adults with AD, recruited nationwide in Sweden, were assessed by telephone, and used the digital intervention for 8 weeks. Participants were also assessed directly afterward and 3 months after the end of the intervention. There was no therapist guidance. Feasibility indicators included intervention credibility, usability, and possible adverse effects. Other measures included preliminary effects on dermatological quality of life, itching sensations, depressive symptoms, and perceived stress.

Results: The intervention was regarded as credible and no serious adverse events were reported. System usability was, however, found to be below the predetermined cutoff for acceptable usability. Preliminary effects at 3-month follow-up were in the moderate to large range for dermatological quality of life (Cohen d=0.89, 95% CI 0.18-1.56), itching sensations (Cohen d=0.85, 95% CI 0.15-1.52), depressive symptoms (Cohen d=0.78, 95% CI 0.1-1.45), and perceived stress (Cohen d=0.75, 95% CI 0.01-1.36).

Conclusions: This 8-week self-management digital CBT-based intervention was, together with telephone calls before and after, a feasible intervention for participants with AD. Preliminary effects were promising and should be explored further in a randomized controlled trial. Intervention usability was, however, rated below cutoff scores. Efforts should be made to improve written material to increase usability.

Keywords: CBT; atopic dermatitis; cognitive behavioral therapy; depression; depressive; dermatitis; dermatology; digital health; digital intervention; eczema; mental health; pruritus; self-guided; self-help; self-management; skin; stress.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: BL owns shares in DahliaQomit, which specializes in web-based services for symptom assessment outside the submitted work, and licenses a cognitive behavioral therapy manual for irritable bowel syndrome, with royalties received from Pear Therapeutics.

Figures

Figure 1
Figure 1
Study flowchart based on the Consolidated Standards Of Reporting Trials 2010 flow diagram.
Figure 2
Figure 2
Levels of severity based on the self-rated Patient-Oriented Eczema Scale reported by Kern et al [13]. FU: 3-month follow-up; POST: postintervention; PRE: preintervention.

References

    1. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016 Mar;387(10023):1109–1122. doi: 10.1016/s0140-6736(15)00149-x. - DOI - PubMed
    1. Sandhu JK, Wu KK, Bui T, Armstrong AW. Association between atopic dermatitis and suicidality: a systematic review and meta-analysis. JAMA Dermatol. 2019 Feb 01;155(2):178–187. doi: 10.1001/jamadermatol.2018.4566. https://europepmc.org/abstract/MED/30540348 2717582 - DOI - PMC - PubMed
    1. Silverberg J, Gelfand J, Margolis D, Boguniewicz M, Fonacier L, Grayson M, Ong P, Chiesa Fuxench Z, Simpson E. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol. 2019 Sep 05;181(3):554–565. doi: 10.1111/bjd.17683. https://europepmc.org/abstract/MED/30838645 - DOI - PMC - PubMed
    1. Wahlgren C. Itch and atopic dermatitis: an overview. J Dermatol. 1999 Nov 09;26(11):770–779. doi: 10.1111/j.1346-8138.1999.tb02090.x. - DOI - PubMed
    1. Verhoeven L, Kraaimaat F, Duller P, van de Kerkhof Peter, Evers A. Cognitive, behavioral, and physiological reactivity to chronic itching: analogies to chronic pain. Int J Behav Med. 2006 Sep;13(3):237–243. doi: 10.1207/s15327558ijbm1303_7. - DOI - PubMed

LinkOut - more resources